izpis_h1_title_alt

An LC-MS/MS method for quantification of lamotrigine and its main metabolite in dried blood spots
ID Milosheska, Daniela (Author), ID Roškar, Robert (Author), ID Vovk, Tomaž (Author), ID Lorber, Bogdan (Author), ID Grabnar, Iztok (Author), ID Trontelj, Jurij (Author)

.pdfPDF - Presentation file, Download (2,87 MB)
MD5: CA6DA12A4BC76D6FD2F8E3C8F133899F
URLURL - Source URL, Visit https://www.mdpi.com/1424-8247/17/4/449 This link opens in a new window

Abstract
Background: The antiepileptic drug lamotrigine (LTG) shows high pharmacokinetic variability due to genotype influence and concomitant use of glucuronidation inducers and inhibitors, both of which may be frequently taken by elderly patients. Our goal was to develop a reliable quantification method for lamotrigine and its main glucuronide metabolite lamotrigine-N2-glucuronide (LTG-N2-GLU) in dried blood spots (DBS) to enable routine therapeutic drug monitoring and to identify altered metabolic activity for early detection of drug interactions possibly leading to suboptimal drug response. Results: The analytical method was validated in terms of selectivity, accuracy, precision, matrix effects, haematocrit, blood spot volume influence, and stability. It was applied to a clinical study, and the DBS results were compared to the concentrations determined in plasma samples. A good correlation was established for both analytes in DBS and plasma samples, taking into account the haematocrit and blood cell-to-plasma partition coefficients. It was demonstrated that the method is suitable for the determination of the metabolite-to-parent ratio to reveal the metabolic status of individual patients. Conclusions: The clinical validation performed confirmed that the DBS technique is a reliable alternative for plasma lamotrigine and its glucuronide determination.

Language:English
Keywords:dried blood spot, lamotrigine, lamotrigine glucuronide, therapeutic drug monitoring, clinical validation, haematocrit effect
Work type:Article
Typology:1.01 - Original Scientific Article
Organization:FFA - Faculty of Pharmacy
Publication status:Published
Publication version:Version of Record
Year:2024
Number of pages:16 str.
Numbering:Vol. 17, art. 449
PID:20.500.12556/RUL-155604 This link opens in a new window
UDC:615.015:616.853
ISSN on article:1424-8247
DOI:10.3390/ph17040449 This link opens in a new window
COBISS.SI-ID:191424771 This link opens in a new window
Publication date in RUL:08.04.2024
Views:57
Downloads:5
Metadata:XML RDF-CHPDL DC-XML DC-RDF
:
Copy citation
Share:Bookmark and Share

Record is a part of a journal

Title:Pharmaceuticals
Shortened title:Pharmaceuticals
Publisher:MDPI
ISSN:1424-8247
COBISS.SI-ID:517582617 This link opens in a new window

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.

Secondary language

Language:Slovenian
Keywords:epileptični napadi, farmakokinetika, posušena krvna lisa, lamotrigin, lamotrigin glukuronid, terapevtsko spremljanje zdravil, klinična validacija, učinek hematokrita

Projects

Funder:ARRS - Slovenian Research Agency
Project number:P1-0189
Name:Farmacevtska tehnologija: od dostavnih sistemov učinkovin do terapijskih izidov zdravil pri otrocih in starostnikih

Funder:Other - Other funder or multiple funders
Funding programme:Ad Futura Scientific and Educational Foundation of the Republic of Slovenia

Similar documents

Similar works from RUL:
Similar works from other Slovenian collections:

Back